Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.
| Revenue (Most Recent Fiscal Year) | $79.95M |
| Net Income (Most Recent Fiscal Year) | $-4.60M |
| PE Ratio (Current Year Earnings Estimate) | 55.08 |
| PE Ratio (Trailing 12 Months) | 163.05 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 16.77 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 36.43 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 0.01M |
| Pre-Tax Margin (Trailing 12 Months) | 12.07% |
| Net Margin (Trailing 12 Months) | 12.02% |
| Return on Equity (Trailing 12 Months) | 40.13% |
| Return on Assets (Trailing 12 Months) | 12.37% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.30 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.41 |
| Inventory Turnover (Trailing 12 Months) | 3.13 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.63 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.35 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.17 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.38 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 28.58M |
| Free Float | 23.87M |
| Market Capitalization | $1.77B |
| Average Volume (Last 20 Days) | 0.70M |
| Beta (Past 60 Months) | 0.90 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.49% |
| Percentage Held By Institutions (Latest 13F Reports) | 27.86% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |